RxDoctor Payments Data

Luis Sanchez Russo, MD

Nephrology · Kissimmee, FLNPI 1043661077

Payments from drug & device makers

$20,668in general payments, 2019–2025

Across 194 payments — averaging $106.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ANI Pharmaceuticals, Inc.$11K
  • Calliditas Therapeutics US Inc.$5K
  • Travere Therapeutics, Inc.$1K
  • Apellis Pharmaceuticals, Inc.$786
  • Novartis$441
  • AstraZeneca$382
  • plus $2K from 22 others

What the payments were for

  • Consulting fees$2,70013%
  • Speaking & faculty fees$9,65047%
  • Travel & lodging$2,68613%
  • Food & beverage$5,54327%
  • Education$890%

General payments by program year

20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,668 in reported general payments places this provider in the 80th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$168,371
Medicare patients
351
Services billed
1,351

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin76$50,484
FarxigaDapagliflozin Propanediol49$36,314
Sevelamer Carbonate13$3,373
Torsemide48$367
Carvedilol25$295
Nifedipine ErNifedipine14$262
Calcitriol28$234
Lisinopril79$167
Amlodipine Besylate35$156
Losartan Potassium25$143
Chlorthalidone12$55

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$382$36,31449 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 756 nephrology providers in Florida.

Other nephrology in Kissimmee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →